irinotecan has been researched along with 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M | 1 |
| Choe, E; Choi, YH; Jeong, NY; Lee, HJ; Lee, JS; Oh, S; Park, BS; Yoo, KS; Yoo, YH | 1 |
2 other study(ies) available for irinotecan and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin | 2012 |
Fatty acid synthase inhibitor cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis.
Topics: Apoptosis; Camptothecin; Cell Survival; Cerulenin; Chromones; DNA Topoisomerases, Type I; Drug Synergism; Fatty Acid Synthases; Humans; Irinotecan; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2013 |